Paper Details

  1. Home
  2. Paper Details

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.

Author: ArnstenA F, ChappellP B, CohenD J, KatsovichL, KimY S, LeckmanJ F, ScahillL, SchultzR T, ShepherdE

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

Guanfacine was found to be a safe and effective treatment for children with tic disorders and ADHD. In a double-blind, placebo-controlled study, guanfacine was associated with a 37% improvement in ADHD symptoms, compared to an 8% improvement in the placebo group. Guanfacine also resulted in a 31% decrease in tic severity, compared to no change in the placebo group.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: This study evaluated the efficacy and safety of guanfacine in treating children with tic disorders and attention deficit hyperactivity disorder (ADHD). METHOD: Subjects from a specialty tic disorders clinic were randomly assigned to receive 8 weeks of treatment with guanfacine or placebo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1176/appi.ajp.158.7.1067

データ提供：米国国立医学図書館（NLM）

Guanfacine: A Potential Oasis for Children with Tic Disorders and ADHD

The vast desert of attention-deficit/hyperactivity disorder (ADHD) and tic disorders can be a challenging terrain for children. This research navigates this landscape by evaluating the efficacy and safety of guanfacine in treating these conditions. The researchers conducted a double-blind, placebo-controlled study with children from a specialized tic disorders clinic. Their findings reveal a significant improvement in ADHD symptoms, as measured by the teacher-rated ADHD Rating Scale, among those treated with guanfacine. The study also demonstrates a reduction in tic severity with guanfacine. These findings suggest that guanfacine may provide a valuable tool for managing ADHD and tic disorders in children.

Guanfacine: A Potential Oasis for Children with Tic Disorders and ADHD

The study's findings demonstrate that guanfacine is a safe and effective treatment for children with tic disorders and ADHD. It is important to note that guanfacine is more effective for ADHD symptoms as rated by teachers than by parents. Further research is needed to understand the reasons for this discrepancy and to determine the long-term effects of guanfacine.

Guanfacine: A Potential Oasis for Children with Tic Disorders and ADHD

This study provides a glimmer of hope for families navigating the challenging landscape of ADHD and tic disorders. Guanfacine appears to be a safe and effective treatment option. As with any medication, careful monitoring and a thorough understanding of potential side effects are essential.

Dr.Camel's Conclusion

This research provides a valuable insight into the potential of guanfacine as a treatment for children with tic disorders and ADHD. However, further research is needed to understand the long-term effects and potential variations in individual responses. Just as an oasis provides a respite for weary travelers in the desert, guanfacine may offer relief for children struggling with these conditions.

Date :
  1. Date Completed 2001-07-26
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

11431228

DOI: Digital Object Identifier

10.1176/appi.ajp.158.7.1067

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.